Why the study?
Do direct oral anticoagulants improve safety and reduce bleeding compared to heparin/warfarin in patients with atrial fibrillation undergoing cardioversion?
Do direct oral anticoagulants improve safety and reduce bleeding compared to heparin/warfarin in patients with atrial fibrillation undergoing cardioversion?
Direct oral anticoagulants are a safe and effective alternative to heparin/warfarin for patients with atrial fibrillation undergoing cardioversion, offering reduced bleeding risk and improved quality of life.
May support DOAC preference in AF cardioversion; leaves open prospective trial confirmation.
Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real "epidemic phenomenon". Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in bleedings and increase in the safety and quality of life of patients.
No takes yet. Share an insight, caveat, or question.
Coppola et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: